Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 3, 2011, Pages 340-348

  Taxonera, C ^a   Estelles J ^a   Fernandez Blanco I ^b   Merino, O ^c   Marin Jimenez I ^d   Barreiro De Acosta, M ^e   Saro, C ^f   Garcia Sanchez V ^g   Gento, E ^h   Bastida, G ⁱ   Gisbert, J P ^j,k   Vera, I ^l   Martinez Montiel, P ^m   Garcia Moran S ^h   Sanchez M C ^j   Mendoza, J L ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL DE CRUCES   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e Hospital Clinico Universitario   (Spain)

^f HOSPITAL DE CABUEÑES   (Spain)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^h HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

ⁱ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^j HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^k HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^l HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^m INSTITUTO DE SALUD CARLOS III   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN A; INFLIXIMAB; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; COLON RESECTION; CONTROLLED STUDY; COUGHING; DELAYED HYPERSENSITIVITY; DISEASE DURATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; LOADING DRUG DOSE; LUPUS LIKE SYNDROME; MAINTENANCE THERAPY; MALE; OUTCOME ASSESSMENT; OVARY CYST; PREDICTION; PRIORITY JOURNAL; PSORIASIS; REMISSION; SMOKING HABIT; TERATOMA; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLECTOMY; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETREATMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 78650892656     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04531.x     Document Type: Article

References (26)

1. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13. (Pubitemid 38182297)
2. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-85.
3. Colombel FJ, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
4. Sandborn WJ, Rutgeerts P, Ems R, et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab. Ann Intern Med 2007; 146: 829-38.
5. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76. (Pubitemid 41770166)
6. Gisbert JP, Gonzalez-Lama Y, Maté J,. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007; 25: 19-37.
7. Baert F, Norman M, Vermeire S, et al. Influence of immunogenicity on the long term efficacy of infliximab in Crohn's disease. N Eng J Med 2003; 348: 601-8. (Pubitemid 36204954)
8. Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA,. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007; 13: 2328-32. (Pubitemid 46860734)
9. Oussalah A, Laclotte C, Chevaux JB, et al. Long-term outcome of adalimumab for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008; 28: 966-72.
10. Afif W, Leighton JA, Hanauer SB, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009; 15: 1302-7.
11. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Ulcerative colitis clinical classification. Can J Gastroenterol 2005; 19 (Suppl. A): 9A-13A.
12. Colombel JF, Sandborn WJ, Reinisch W, et al., SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
13. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-8.
14. Reinisch W, Lofberg R, Louis E, et al. Adalimumab effectiveness in TNF-antagonist-naive patients and in infliximab nonresponders with Crohn's disease: results from the CARE study. Am J Gastroenterol 2008; 103: A1068.
15. Seiderer J, Brand S, Dambacher J, et al. Adalimumab in patients with Crohn's disease-safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther 2007; 25: 787-96.
16. Ho GT, Mowat A, Potts L, et al. Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008). Aliment Pharmacol Ther 2009; 29: 527-34.
17. Barreiro-de Acosta M, Lorenzo A, Dominguez-Muñoz JE,. Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years. World J Gastroenterol 2009; 15: 3814-6.
18. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis. Gastroenterology 2010; 138 (Suppl. 1): S-114-5.
19. Loftus EV, Delgado DJ, Friedman HS, Sandborn WJ,. Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States. Am J Gastroenterol 2008; 103: 1737-45.
20. Lepisto A, Luukkonen P, Jarvinen HJ,. Cumulative failure rate of ileal pouch-anal anastomosis and quality of life after failure. Dis Colon Rectum 2002; 45: 1289-94.
21. Tulchinsky H, Hawley PR, Nicholls J,. Long-term failure after restorative proctocolectomy for ulcerative colitis. Ann Surg 2003; 238: 229-34.
22. Johnson P, Richard C, Ravid A, et al. Female infertility after ileal pouchanal anastomosis for ulcerative colitis. Dis Colon Rectum 2004; 47: 1119-26.
23. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137: 1250-60.
24. Ferrante M, Vermiere S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohn's Colitis 2008; 2: 219-25.
25. Gies N, Kroeker I, Wong K, et al. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther 2010; 32: 522-8.
26. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 1133-9.